LncFAL inhibits ex vivo anti-tumor activity by directly binding to and competitively attenuating FSP1-dependent Trim69 ubiquitination, reducing susceptibility to ferroptosis and inhibiting ex vivo anti-tumor activity (50). Here, TRIM69 is linked to neoplasm.